Excessive GSK-3β function, which is frequently observed in tumor initiation, promotes progression and contributes to drug resistance by harassing signaling pathways including the Wnt/β-catenin, PI3K-AKT-mTOR, and JAK2/STAT3 signaling pathways [34–36]. The gene discussed is GSK3B; the disease is neoplasm.